The Oxford-AstraZeneca vaccine has been approved for use in the UK, with the first doses due to be given on Monday amid rising coronavirus cases.
The UK has ordered 100 million doses - enough to vaccinate 50 million people.
AstraZeneca chief executive, Pascal Soriot, told the Sunday Times more tests were needed to be sure, but hailed the discovery of what he called a “winning formula” to improve the vaccine’s efficacy.
Trio’s pledge comes as FDA works towards vaccine approval
Overall results showed 70% protection, but the researchers say the figure may be as high as 90% by tweaking the dose.
President Donald Trump called coronavirus expert Anthony Fauci a “disaster” on Monday, airing his frustration with the scientist during a call meant to reassure campaign staff he has a path to victory on Nov. 3 despite trailing in opinion polls.
The regulatory filing for the vaccine could come as soon as safety data is available, possibly in the third week of November, Pfizer said, lifting the company’s shares and the broader U.S. stock market.
AstraZeneca Plc and Oxford pause major vaccine trial for second time.
Taiwan-based Medigen Vaccine Biologics Corp. (MVC) announced Monday that it has teamed up with the U.S. National Institutes of Health (NIH) to develop a vaccine against COVID-19 coronavirus.
